A Phase 3 interventional study of MRTX849 and Docetaxel in Metastatic Non Small Cell Lung Cancer and Advanced Non Small Cell Lung Cancer, sponsored by Mirati Therapeutics Inc.. Active, not recruiting at 380 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 7 under way, 3 of them phase 3. adagrasib · Carcinoma, Non-Small-Cell Lung.
Among the 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 3, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Mirati Therapeutics Inc. · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
Ryan Gentzler, MD · Sites in United States
Ages 18+
Mirati Therapeutics Inc. · Sites in United States, Argentina, Australia and 44 more countries
Ages 18+
By country, each count listing its studies:
adagrasib: first FDA approval 2022 (KRAZATI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3
First in 2020; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 77 across the 12 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Mirati Therapeutics Inc., one of the names counted as Bristol-Myers Squibb. Under that name alone:
Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 25th largest by enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2021, is one of 27 in phase 3, reaches primary completion later than 1 of the 34 other live ones, and was the 82nd registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
1 of the studies testing adagrasib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06248606Ryan Gentzler, MDAdagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | 2027-02-25 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Crossover Inclusion Criteria:
Exclusion Criteria:
Crossover Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MRTX849
Drug: Docetaxel
Progression-Free Survival (PFS) as Per Blinded Independent Central Review
Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)
Overall Survival (OS)
Overall survival is defined as the time from randomization to the date of death due to any cause.
Time frame: From randomization till death due to any cause (up to approximately 143 weeks)
Objective Response Rate (ORR) as Per Blinded Independent Central Review
Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
Time frame: From randomization till death or till disease progression or initiation of follow-up anti-cancer therapy or withdrawal of consent prior to minimum efficacy follow-up (up to 143 weeks)
Duration of Response (DOR) as Per Blinded Independent Central Review
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
Time frame: First documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause (Up to approximately 22 months)
1-Year Survival Rate
Time frame: Up to 49 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters
Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters
Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Plasma Concentration of Adagrasib
Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.
Time frame: Day 1 of Cycle 1 (Pre-Dose and Peak), Cycle 2 (Pre-Dose and Peak), Cycle 3 (Pre-Dose), Cycle 5 (Pre-Dose), Cycle 7 (Pre-Dose) (Each cycle is of 21 days)
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Least Square Mean and Confidence Interval are from a repeated measures model on the response variable change from baseline in LCSS average total score.
Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.
Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average 3-item global index score assesses the following 3 items (Distress/severity of symptoms from lung cancer, impact on normal activities, quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The 3 item global index score is average of all the 3 items ranging from 0 to 100 where high score represent worst outcome. LS mean and CI are from a repeated measures model on the response variable change from baseline in 3-item global index score.
Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score
The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.
Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.
Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
| Milestone | Adagrasib | Docetaxel |
|---|---|---|
| Started | 301 | 152 |
| Safety population | 298 | 140 |
| Cross over | 0 | 44 |
| Completed | 163 | 83 |
| Not completed | 138 | 69 |
| Withdrew: Death | 126 | 53 |
| Withdrew: Withdrawal by subject | 12 | 16 |
Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Adagrasib | Docetaxel |
|---|---|---|
| Progression-Free Survival (PFS) as Per Blinded Independent Central Review | 5.49 (4.53 to 6.67) | 3.84 (2.73 to 4.73) |
Overall survival is defined as the time from randomization to the date of death due to any cause.
Results for this outcome have not been posted.
Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
| percentage of participants | Adagrasib | Docetaxel |
|---|---|---|
| Objective Response Rate (ORR) as Per Blinded Independent Central Review | 31.9 (26.7 to 37.5) | 9.2 (5.1 to 15.0) |
Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.
| months | Adagrasib | Docetaxel |
|---|---|---|
| Duration of Response (DOR) as Per Blinded Independent Central Review | 8.31 (6.05 to 10.35) | 5.36 (2.86 to 8.54) |
Results for this outcome have not been posted.
Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Adagrasib | Docetaxel | Crossover Adagrasib |
|---|---|---|---|
| Any TEAE | 298 | 138 | 44 |
| Any Treatment-Related TEAE | 280 | 121 | 41 |
| Any Treatment-Emergent SAE | 149 | 50 | 20 |
| Any Treatment-Related Treatment-Emergent SAE | 62 | 23 | 7 |
| Any TEAE Leading to Discontinuation of Treatment | 40 | 25 | 2 |
Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
| Participants | Adagrasib | Docetaxel | Crossover Adagrasib |
|---|---|---|---|
| Anemia Grade 0 | 50 | 16 | 5 |
| Anemia Grade 1 | 155 | 74 | 26 |
| Anemia Grade 2 | 74 | 34 | 7 |
| Anemia Grade 3 | 16 | 8 | 3 |
| Anemia Grade 4 | 0 | 0 | 0 |
| Anemia Missing | 3 | 8 | 3 |
| Lymphocytes count decreased Grade 0 | 61 | 33 | 9 |
| Lymphocytes count decreased Grade 1 | 66 | 20 | 7 |
| Lymphocytes count decreased Grade 2 | 71 | 33 | 10 |
| Lymphocytes count decreased Grade 3 | 52 | 23 | 9 |
| Lymphocytes count decreased Grade 4 | 8 | 3 | 0 |
| Lymphocytes count decreased Missing | 40 | 28 | 9 |
| Neutrophils count decreased Grade 0 | 227 | 61 | 32 |
| Neutrophils count decreased Grade 1 | 10 | 13 | 0 |
| Neutrophils count decreased Grade 2 | 8 | 7 | 0 |
| Neutrophils count decreased Grade 3 | 4 | 10 | 1 |
| Neutrophils count decreased Grade 4 | 8 | 21 | 2 |
| Neutrophils count decreased Missing | 41 | 28 | 9 |
| Platelets count decreased Grade 0 | 208 | 113 | 35 |
| Platelets count decreased Grade 1 | 74 | 13 | 6 |
| Platelets count decreased Grade 2 | 8 | 3 | 0 |
| Platelets count decreased Grade 3 | 1 | 0 | 0 |
| Platelets count decreased Grade 4 | 3 | 0 | 0 |
| Platelets count decreased Missing | 4 | 11 | 3 |
| White blood cell decreased Grade 0 | 235 | 72 | 36 |
| White blood cell decreased Grade 1 | 36 | 14 | 3 |
| White blood cell decreased Grade 2 | 16 | 15 | 1 |
| White blood cell decreased Grade 3 | 7 | 24 | 0 |
| White blood cell decreased Grade 4 | 0 | 4 | 1 |
| White blood cell decreased Missing | 4 | 11 | 3 |
Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.
| Participants | Adagrasib | Docetaxel | Crossover Adagrasib |
|---|---|---|---|
| Alanine Aminotransferase increased Grade 0 | 118 | 118 | 23 |
| Alanine Aminotransferase increased Grade 1 | 107 | 12 | 11 |
| Alanine Aminotransferase increased Grade 2 | 23 | 0 | 4 |
| Alanine Aminotransferase increased Grade 3 | 34 | 0 | 1 |
| Alanine Aminotransferase increased Grade 4 | 5 | 0 | 0 |
| Alanine Aminotransferase increased Missing | 11 | 10 | 5 |
| Hypoalbuminemia Grade 0 | 118 | 55 | 19 |
| Hypoalbuminemia Grade 1 | 109 | 51 | 13 |
| Hypoalbuminemia Grade 2 | 58 | 22 | 7 |
| Hypoalbuminemia Grade 3 | 1 | 0 | 0 |
| Hypoalbuminemia Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia Missing | 12 | 12 | 5 |
| Hypercalcemia Grade 0 | 260 | 108 | 35 |
| Hypercalcemia Grade 1 | 24 | 19 | 3 |
| Hypercalcemia Grade 2 | 1 | 0 | 0 |
| Hypercalcemia Grade 3 | 0 | 0 | 0 |
| Hypercalcemia Grade 4 | 1 | 0 | 0 |
| Hypercalcemia Missing | 12 | 13 | 6 |
| Hypocalcemia Grade 0 | 230 | 111 | 25 |
| Hypocalcemia Grade 1 | 45 | 14 | 11 |
| Hypocalcemia Grade 2 | 11 | 2 | 2 |
| Hypocalcemia Grade 3 | 0 | 0 | 0 |
| Hypocalcemia Grade 4 | 0 | 0 | 0 |
| Hypocalcemia Missing | 12 | 13 | 6 |
| Alkaline Phosphatase increased Grade 0 | 165 | 109 | 24 |
| Alkaline Phosphatase increased Grade 1 | 82 | 19 | 14 |
| Alkaline Phosphatase increased Grade 2 | 31 | 2 | 1 |
| Alkaline Phosphatase increased Grade 3 | 8 | 0 | 0 |
| Alkaline Phosphatase increased Grade 4 | 1 | 0 | 0 |
| Alkaline Phosphatase increased Missing | 11 | 10 | 5 |
| Amylase increased Grade 0 | 181 | 107 | 31 |
| Amylase increased Grade 1 | 65 | 11 | 7 |
| Amylase increased Grade 2 | 16 | 3 | 1 |
| Amylase increased Grade 3 | 6 | 0 | 0 |
| Amylase increased Grade 4 | 0 | 0 | 0 |
| Amylase increased Missing | 30 | 19 | 5 |
| Aspartate Aminotransferase increased Grade 0 | 103 | 115 | 25 |
| Aspartate Aminotransferase increased Grade 1 | 133 | 14 | 13 |
| Aspartate Aminotransferase increased Grade 2 | 27 | 0 | 1 |
| Aspartate Aminotransferase increased Grade 3 | 20 | 0 | 0 |
| Aspartate Aminotransferase increased Grade 4 | 3 | 0 | 0 |
| Aspartate Aminotransferase increased Missing | 12 | 11 | 5 |
| Bilirubin increased Grade 0 | 251 | 125 | 37 |
| Bilirubin increased Grade 1 | 24 | 2 | 1 |
| Bilirubin increased Grade 2 | 9 | 1 | 1 |
| Bilirubin increased Grade 3 | 1 | 0 | 0 |
| Bilirubin increased Grade 4 | 2 | 0 | 0 |
| Bilirubin increased Missing | 11 | 12 | 5 |
| Creatinine increased Grade 0 | 99 | 99 | 14 |
| Creatinine increased Grade 1 | 55 | 17 | 9 |
| Creatinine increased Grade 2 | 126 | 11 | 15 |
| Creatinine increased Grade 3 | 6 | 3 | 1 |
| Creatinine increased Grade 4 | 1 | 0 | 0 |
| Creatinine increased Missing | 11 | 10 | 5 |
| Fasted Hypoglycemia Grade 0 | 146 | 64 | 18 |
| Fasted Hypoglycemia Grade 1 | 15 | 4 | 2 |
| Fasted Hypoglycemia Grade 2 | 1 | 0 | 1 |
| Fasted Hypoglycemia Grade 3 | 0 | 0 | 0 |
| Fasted Hypoglycemia Grade 4 | 2 | 0 | 0 |
| Fasted Hypoglycemia Missing | 134 | 72 | 23 |
| Lipase Increased Grade 0 | 177 | 109 | 28 |
| Lipase Increased Grade 1 | 63 | 9 | 7 |
| Lipase Increased Grade 2 | 27 | 6 | 2 |
| Lipase Increased Grade 3 | 13 | 0 | 1 |
| Lipase Increased Grade 4 | 0 | 0 | 0 |
| Lipase Increased Missing | 18 | 16 | 6 |
| Hypermagnesemia Grade 0 | 265 | 122 | 37 |
| Hypermagnesemia Grade 1 | 19 | 4 | 2 |
| Hypermagnesemia Grade 2 | 0 | 0 | 0 |
| Hypermagnesemia Grade 3 | 1 | 1 | 0 |
| Hypermagnesemia Grade 4 | 0 | 0 | 0 |
| Hypermagnesemia Missing | 13 | 13 | 5 |
| Hypomagnesemia Grade 0 | 213 | 99 | 29 |
| Hypomagnesemia Grade 1 | 67 | 25 | 10 |
| Hypomagnesemia Grade 2 | 5 | 3 | 0 |
| Hypomagnesemia Grade 3 | 0 | 0 | 0 |
| Hypomagnesemia Grade 4 | 0 | 0 | 0 |
| Hypomagnesemia Missing | 13 | 13 | 5 |
| Non-Fasted Hypoglycemia Grade 0 | 163 | 66 | 22 |
| Non-Fasted Hypoglycemia Grade 1 | 9 | 8 | 3 |
| Non-Fasted Hypoglycemia Grade 2 | 1 | 0 | 0 |
| Non-Fasted Hypoglycemia Grade 3 | 0 | 0 | 0 |
| Non-Fasted Hypoglycemia Grade 4 | 3 | 0 | 0 |
| Non-Fasted Hypoglycemia Missing | 122 | 66 | 19 |
| Hyperkalemia Grade 0 | 206 | 107 | 28 |
| Hyperkalemia Grade 1 | 54 | 15 | 8 |
| Hyperkalemia Grade 2 | 20 | 6 | 3 |
| Hyperkalemia Grade 3 | 5 | 0 | 0 |
| Hyperkalemia Grade 4 | 1 | 1 | 0 |
| Hyperkalemia Missing | 12 | 11 | 5 |
| Hypokalemia Grade 0 | 237 | 114 | 36 |
| Hypokalemia Grade 1 | 43 | 11 | 2 |
| Hypokalemia Grade 2 | 0 | 0 | 0 |
| Hypokalemia Grade 3 | 6 | 3 | 0 |
| Hypokalemia Grade 4 | 0 | 1 | 1 |
| Hypokalemia Missing | 12 | 11 | 5 |
| Hypernatremia Grade 0 | 272 | 130 | 39 |
| Hypernatremia Grade 1 | 14 | 0 | 0 |
| Hypernatremia Grade 2 | 0 | 0 | 0 |
| Hypernatremia Grade 3 | 1 | 0 | 0 |
| Hypernatremia Grade 4 | 0 | 0 | 0 |
| Hypernatremia Missing | 11 | 10 | 5 |
| Hyponatremia Grade 0 | 135 | 95 | 18 |
| Hyponatremia Grade 1 | 126 | 32 | 19 |
| Hyponatremia Grade 2 | 17 | 3 | 1 |
| Hyponatremia Grade 3 | 7 | 0 | 0 |
| Hyponatremia Grade 4 | 2 | 0 | 1 |
| Hyponatremia Missing | 11 | 10 | 5 |
| Hyperuricemia Grade 0 | 185 | 103 | 22 |
| Hyperuricemia Grade 1 | 98 | 22 | 17 |
| Hyperuricemia Grade 2 | 0 | 0 | 0 |
| Hyperuricemia Grade 3 | 0 | 0 | 0 |
| Hyperuricemia Grade 4 | 0 | 0 | 0 |
| Hyperuricemia Missing | 15 | 15 | 5 |
Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.
| nanogram per milliliter (ng/mL) | Adagrasib 200 mg BID | Adagrasib 400 mg QD | Adagrasib 400 mg BID | Adagrasib 600 mg QD | Adagrasib 600 mg BID |
|---|---|---|---|---|---|
| Cycle 1 Day 1 Pre-Dose | NA ± NA | — | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 1 Peak | NA ± NA | — | NA ± NA | 556.963 ± 63.550 | 518.944 ± 86.625 |
| Cycle 2 Day 1 Pre-Dose | NA ± NA | — | 1579.040 ± 54.432 | NA ± NA | 2097.813 ± 67.912 |
| Cycle 2 Day 1 Peak | — | NA ± NA | 2011.347 ± 39.333 | 2331.298 ± 59.515 | 2117.333 ± 62.744 |
| Cycle 3 Day 1 Pre-Dose | — | — | NA ± NA | NA ± NA | 1865.408 ± 42.930 |
| Cycle 5 Day 1 Pre-Dose | — | — | 1114.046 ± 39.300 | 917.541 ± 73.596 | 1459.470 ± 39.094 |
| Cycle 7 Day 1 Pre-Dose | — | NA ± NA | 1062.114 ± 33.842 | 863.539 ± 42.917 | 1548.018 ± 41.166 |
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Least Square Mean and Confidence Interval are from a repeated measures model on the response variable change from baseline in LCSS average total score.
| Score on a sclae | Adagrasib | Docetaxel |
|---|---|---|
| Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score | -4.0 (-7.9 to -0.2) | 3.9 (-0.2 to 8.0) |
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.
| Score on a sclae | Adagrasib | Docetaxel |
|---|---|---|
| Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score | -5.8 (-9.0 to -2.5) | 3.2 (-0.4 to 6.7) |
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average 3-item global index score assesses the following 3 items (Distress/severity of symptoms from lung cancer, impact on normal activities, quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The 3 item global index score is average of all the 3 items ranging from 0 to 100 where high score represent worst outcome. LS mean and CI are from a repeated measures model on the response variable change from baseline in 3-item global index score.
| Score on a sclae | Adagrasib | Docetaxel |
|---|---|---|
| Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score | -3.0 (-20.3 to 14.3) | 15.9 (-2.6 to 34.3) |
The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.
| Score on a scale | Adagrasib | Docetaxel |
|---|---|---|
| Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score | 0.1 (-4.4 to 4.5) | -3.7 (-8.5 to 1.1) |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.
| Score on a scale | Adagrasib | Docetaxel |
|---|---|---|
| Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score | -0.0350 (-0.0977 to 0.0277) | -0.0914 (-0.1572 to -0.0256) |
Collected over All cause mortality and non serious adverse events were reported from first first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks). Serious adverse events were collected from date of signing of informed consent form till 28 days after last dose (Up to approximately 111 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adagrasib | 126/301 (41.9%) | 149/298 (50%) | 292/298 (98%) |
| Docetaxel | 53/152 (34.9%) | 50/140 (35.7%) | 129/140 (92.1%) |
| Crossover Adagrasib | 15/44 (34.1%) | 20/44 (45.5%) | 43/44 (97.7%) |
| Event | Adagrasib | Docetaxel | Crossover Adagrasib |
|---|---|---|---|
| PneumoniaInfections and infestations | 11/298 | 7/140 | 6/44 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 22/298 | 5/140 | 5/44 |
| DiarrhoeaGastrointestinal disorders | 4/298 | 3/140 | 2/44 |
| VomitingGastrointestinal disorders | 9/298 | 2/140 | 1/44 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/298 | 4/140 | 0/44 |
| PyrexiaGeneral disorders | 7/298 | 1/140 | 0/44 |
| MyelosuppressionBlood and lymphatic system disorders | 0/298 | 2/140 | 1/44 |
| Cardiac failureCardiac disorders | 1/298 | 0/140 | 1/44 |
| Cardio-respiratory arrestCardiac disorders | 0/298 | 2/140 | 1/44 |
| Pericardial effusionCardiac disorders | 0/298 | 1/140 | 1/44 |
| Event | Adagrasib | Docetaxel | Crossover Adagrasib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 169/298 | 42/140 | 29/44 |
| VomitingGastrointestinal disorders | 121/298 | 12/140 | 16/44 |
| NauseaGastrointestinal disorders | 114/298 | 31/140 | 15/44 |
| AnaemiaBlood and lymphatic system disorders | 91/298 | 48/140 | 11/44 |
| Alanine aminotransferase increasedInvestigations | 99/298 | 4/140 | 4/44 |
| Aspartate aminotransferase increasedInvestigations | 99/298 | 2/140 | 5/44 |
| AstheniaGeneral disorders | 81/298 | 46/140 | 9/44 |
| Blood creatinine increasedInvestigations | 82/298 | 4/140 | 14/44 |
| Decreased appetiteMetabolism and nutrition disorders | 94/298 | 34/140 | 12/44 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/298 | 35/140 | 0/44 |
| Age, Continuous(years) | Adagrasib | Docetaxel | Total |
|---|---|---|---|
| Mean | 63.6 ± 8.66 | 63.9 ± 7.81 | 63.7 ± 8.38 |
| Sex: Female, Male(Participants) | Adagrasib | Docetaxel | Total |
|---|---|---|---|
| Female | 108 | 42 | 150 |
| Male | 193 | 110 | 303 |
| Ethnicity (NIH/OMB)(Participants) | Adagrasib | Docetaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 14 |
| Not Hispanic or Latino | 199 | 111 | 310 |
| Unknown or Not Reported | 94 | 35 | 129 |
| Race/Ethnicity, Customized(Participants) | Adagrasib | Docetaxel | Total |
|---|---|---|---|
| White | 135 | 81 | 216 |
| Black or African American | 0 | 0 | 0 |
| Asian | 72 | 37 | 109 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Other | 2 | 1 | 3 |
| Not Reported | 81 | 30 | 111 |
| Missing | 11 | 3 | 14 |
Showing the first 100 of 380 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Feb 2021 to primary completion in Dec 2023, 34 months.
Results were first posted in Jan 2025, 1 year after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adagrasib
Carcinoma, Non-Small-Cell Lung →